You have not yet registered? Get your account for free.
Forgot Password? We will send you a reset link
26 July 2024
Merck KGaA: Strong 2nd Quarter, Guidance raised
24 June 2024
Merck KGaA: Phase III trials of xevinapant in locally advanced head & neck cancer discontinued
5 December 2023
Merck KGaA: Phase III trial results for evobrutinib in relapsing multiple sclerosis did not meet primary endpoint of reducing annualized relapse rates (ARR) compared to oral teriflunomide
3 November 2021
Merck KGaA raises forecast for full year 2021
4 May 2021
20 January 2021
Merck KGaA: Merck KGaA to discontinue bintrafusp alfa clinical trial (INTR@PID Lung 037)
